<DOC>
	<DOCNO>NCT01127087</DOCNO>
	<brief_summary>Hypothesis : Oral administration oxalate metabolize enzyme Oxazyme ( OC4 ) degrade food-borne oxalate hence prevent absorption gastrointestinal tract . In addition , reduce oxalate concentration gastrointestinal fluid , oxalate secretion blood intestinal tract may increase . Both effect would decrease blood level oxalate , hence oxalate excretion urine .</brief_summary>
	<brief_title>Oxazyme Patients With Hyperoxaluria</brief_title>
	<detailed_description>Oxazyme oxalate degrade compound potentially degrade food-borne oxalate hence prevent absorption gastrointestinal tract . We propose 20-patient open-label trial pilot study one month Oxazyme twice daily ( 1gm Oxazyme sachet dissolve 150 ml water ) among adult subject history calcium oxalate nephrolithiasis . Patients stratify enteric hyperoxaluria Roux-en-Y Gastric Bypass ( RYGB , n=10 ) idiopathic hyperoxaluria ( n=10 ) . The patient perform two , 24-hour , urine collection immediately start Oxazyme last two day treatment period .</detailed_description>
	<criteria>RouxenY gastric bypass hyperoxaluric Calcium oxalate ( CaOx ) stone subject Idiopathic hyperoxaluric CaOx stone subject Patients must radioopaque stone present xray , history consistent passage stone stone surgery Extracorporeal Shock Wave Lithotripsy ( ESWL ) last 5 year . Hyperoxaluria Ox/Cr ratio â‰¥36 mg/g The patient must able provide write informed consent Patients must able urinate reliably collection vessel measure urine volume . Patients may take drug prevention stone disease , include pyridoxine , thiazide , citrate supplement allopurinol , long change medication least 3 month Primary hyperoxaluria patient Use Oxadrop , Oxabsorb , therapies affect oxalate absorption gut , stable dos calcium . Subjects pregnant . Women childbearing potential must negative pregnancy test prior enrollment must practice form birth control trial . Patients unstable dose drug prevention stone disease ( i.e. , pyridoxine , citrate supplement . etc. ) . Patients stable dose least 3 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Hyperoxaluria</keyword>
	<keyword>Oxazyme</keyword>
	<keyword>oxalate</keyword>
	<keyword>enteric hyperoxaluria</keyword>
</DOC>